Schering-Plough

Charlotte Hanneman to succeed Abhijit Bhattacharya as Philips’ Chief Financial Officer (CFO)

Retrieved on: 
Wednesday, February 28, 2024

The proposal will be submitted to the Annual General Meeting of Shareholders (AGM), to be held on May 7, 2024.

Key Points: 
  • The proposal will be submitted to the Annual General Meeting of Shareholders (AGM), to be held on May 7, 2024.
  • Ms. Hanneman will join Philips as a member of Philips’ Executive Committee on June 1, 2024, to start her induction and transition into the role, succeeding current CFO Abhijit Bhattacharya on October 1, 2024.
  • In this current role, she is responsible for financial control, enterprise financial planning and analysis, and business development finance.
  • I am fully focused on delivering on Philips’ plan in the next six months and ensuring a seamless handover to Charlotte.”

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

Retrieved on: 
Tuesday, February 20, 2024

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer.

Key Points: 
  • MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer.
  • Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology.
  • Prior to Eiger, he was Executive Vice President and Chief Commercial Officer of Rigel Pharmaceuticals where he built and led the commercial organization and launched Tavalisse® (fostamatinib disodium hexahydrate) for chronic immune thrombocytopenia.
  • “I am excited to join Celcuity and work alongside driven, collaborative colleagues during this pivotal time for the company,” said Eldon Mayer.

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Tuesday, February 27, 2024

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Greenphire Adds Industry Veteran Dan Shannon as New Chief Experience Officer

Retrieved on: 
Monday, February 26, 2024

Greenphire , a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, today announced the addition of healthcare technology executive Dan Shannon as its new Chief Experience Officer (CXO).

Key Points: 
  • Greenphire , a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, today announced the addition of healthcare technology executive Dan Shannon as its new Chief Experience Officer (CXO).
  • View the full release here: https://www.businesswire.com/news/home/20240226687875/en/
    Dan Shannon joins Greenphire as Chief Experience Officer.
  • Company culture and a compelling product set solidified why I wanted to join Greenphire as my next professional endeavor,” Dan said.
  • “I look forward to helping solve challenging problems for our industry and make a bigger impact through optimizing the company’s customer experience.”

Wael Fayad and Stephen Hallenbeck Appointed Partners at Hildred Capital Management

Retrieved on: 
Monday, February 26, 2024

Hildred Capital Management (“Hildred”), a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies, today announced that Wael Fayad and Stephen Hallenbeck have both been appointed Partners at the firm.

Key Points: 
  • Hildred Capital Management (“Hildred”), a healthcare-focused private equity firm that seeks opportunities to create value in middle-market companies, today announced that Wael Fayad and Stephen Hallenbeck have both been appointed Partners at the firm.
  • On behalf of Hildred, Co-Founders and Managing Partners Andrew Goldman and David Solomon stated:
    "We are pleased to announce the promotions of Wael and Stephen, which reflect the vital impact and contributions that each of them has had on the growth of our firm.
  • Wael is an integral part of our team and has been intimately involved in strategically managing several of our portfolio companies, including Carlin Consumer Health, Hyland’s Naturals, and Crown Laboratories.
  • He then worked at Forest Laboratories Inc. for 14 years and served as Corporate Vice President of Business Development.

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

Retrieved on: 
Thursday, February 29, 2024

CARLSBAD, Calif., Feb. 29, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis as executive vice president, chief global product strategy officer, to lead all aspects of commercialization at the Company. Mr. Jenne has more than 25 years of biopharmaceutical commercial and executive leadership experience and has launched innovative medicines across a broad range of therapeutic areas including cardiovascular, neurology and allergy.

Key Points: 
  • Onaiza Cadoret-Manier, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.
  • She has built a stellar team of professionals with deep experience across all aspects of commercialization," said Brett P. Monia, Ionis' chief executive officer.
  • Mr. Jenne previously spent five years in commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020.
  • His most recent role at Ionis was as EVP & chief commercial officer.

Petco Love's National Pet Vaccination Month in March Urges Pet Vaccinations to Save Pet Lives

Retrieved on: 
Thursday, February 29, 2024

SAN ANTONIO, Feb. 29, 2024 /PRNewswire/ -- During March's National Pet Vaccination Month, Petco Love, a national nonprofit organization, reminds pet parents of the importance of vaccinating their pets against deadly, yet preventable diseases in dogs and cats, at their veterinarian or local vaccine clinic. As part of its Vaccinated and Loved campaign and to support access to care for pets across the country, Petco Love is distributing pet vaccines to partner animal welfare organizations to hold free pet vaccine clinics in their communities.

Key Points: 
  • "No pet parent wants to see their pets suffer, especially from a disease that could have been prevented, and we know vaccines save pets lives."
  • Petco Love's Vaccinated and Loved campaign launched in 2021 to encourage Petco Love animal welfare partners to host free vaccine clinics.
  • Since that time, Petco Love distributed over 2.2M vaccines to date and surveyed pet parents1 attending these free clinics to assess their impact.
  • Pet parents in need of free pet vaccinations can visit care.petcolove.org to find a participating clinic.

Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, February 26, 2024

Other expense was $34 million in the fourth quarter of 2023 on a reported basis, compared to $21 million in the fourth quarter of 2022.

Key Points: 
  • Other expense was $34 million in the fourth quarter of 2023 on a reported basis, compared to $21 million in the fourth quarter of 2022.
  • The reported effective tax rate was negative 11.1% in the fourth quarter of 2023 compared to 39.2% in the fourth quarter of 2022.
  • Adjusted EBITDA was $165 million in the fourth quarter of 2023, a decrease of 4% compared to the fourth quarter of 2022.
  • Cash provided by operations was $157 million in the fourth quarter of 2023 compared to $13 million in the fourth quarter of 2022.

Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer

Retrieved on: 
Tuesday, February 13, 2024

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
  • Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
  • Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period.
  • Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis.

Merck Animal Health to Acquire Elanco’s Aqua Business

Retrieved on: 
Monday, February 5, 2024

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.

Key Points: 
  • Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.
  • “We are excited for the acquisition of Elanco’s aqua products, solutions as well as the capabilities and expertise the team brings to our business,” said Rick DeLuca, president, Merck Animal Health.
  • The addition of this innovative portfolio of cold water and warm water aqua products across vaccines, anti-parasitic treatments, water supplements and nutrition, will establish Merck Animal Health as a leader in aqua.”
    Elanco Animal Health President and CEO Jeff Simmons said, “Following a robust process over the last year, Merck Animal Health emerged as the right strategic buyer for the aquaculture business.
  • In March 2019, Merck Animal Health acquired Scan Aqua AS, a fish health and fish welfare company based in Norway, focused on key aqua products.